Next Article in Journal
Norepinephrine Regulation of Ventromedial Hypothalamic Nucleus Metabolic-Sensory Neuron 5′-AMP-Activated Protein Kinase Activity: Impact of Estradiol
Next Article in Special Issue
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
Previous Article in Journal
Adiponectin and Cognitive Decline
Previous Article in Special Issue
PTX3 Modulates Neovascularization and Immune Inflammatory Infiltrate in a Murine Model of Fibrosarcoma
Review

The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments

1
Section of Epidemiology and Population Science, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA
2
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada Di Fiume 447, 34149 Trieste, Italy
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(6), 2011; https://doi.org/10.3390/ijms21062011
Received: 24 February 2020 / Revised: 11 March 2020 / Accepted: 14 March 2020 / Published: 16 March 2020
(This article belongs to the Special Issue FGF/FGFR Signaling Pathway in Development and Human Diseases)
Breast cancer (BC) is the most frequent form of malignancy and second only to lung cancer as cause of deaths in women. Notwithstanding many progresses made in the field, metastatic BC has a very poor prognosis. As therapies are becoming more personalized to meet the needs of patients, a better knowledge of the molecular biology leading to the disease unfolds the possibility to project more precise compounds or antibodies targeting definite alteration at the molecular level and functioning on such cancer-causing molecules expressed in cancer cells of patients, or present as antigens on the surface of cancer cell membranes. Fibroblast growth factor receptor (FGFR) is one of such druggable targets, activated by its own ligands -namely the Fibroblast Growth Factors (FGFs). This pathway provides a vast range of interesting molecular targets pursued at different levels of clinical investigation. Herein we provide an update on the knowledge of genetic alterations of the receptors in breast cancer, their role in tumorigenesis and the most recent drugs against this particular receptor for the treatment of the disease. View Full-Text
Keywords: metastatic breast cancer; targeted therapies; fibroblast growth factors’ receptors drugs metastatic breast cancer; targeted therapies; fibroblast growth factors’ receptors drugs
Show Figures

Figure 1

MDPI and ACS Style

Sobhani, N.; Fan, C.; O. Flores-Villanueva, P.; Generali, D.; Li, Y. The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments. Int. J. Mol. Sci. 2020, 21, 2011. https://doi.org/10.3390/ijms21062011

AMA Style

Sobhani N, Fan C, O. Flores-Villanueva P, Generali D, Li Y. The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments. International Journal of Molecular Sciences. 2020; 21(6):2011. https://doi.org/10.3390/ijms21062011

Chicago/Turabian Style

Sobhani, Navid, Chunmei Fan, Pedro O. Flores-Villanueva, Daniele Generali, and Yong Li. 2020. "The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments" International Journal of Molecular Sciences 21, no. 6: 2011. https://doi.org/10.3390/ijms21062011

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop